









Markets
/
Stocks
/
nasdaq-lyel
/

Lyell Immunopharma Inc

LYEL

17.510USD

-0.370-2.07%

Close 11/07, 16:00（ET）Quotes delayed by 15 min

259.69MMarket Cap

LossP/E TTM



Lyell Immunopharma Inc

17.510

-0.370-2.07%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Lyell Immunopharma Inc

Currency: USD Updated: 2025-11-06

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Lyell Immunopharma Inc's Score

Industry at a Glance

Industry Ranking

125 / 407

Overall Ranking

246 / 4615

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Hold

Current Rating

14.000

Target Price

-15.36%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Lyell Immunopharma Inc Highlights

StrengthsRisks

Lyell Immunopharma, Inc. is a clinical-stage cell therapy company advancing a pipeline of product candidates enhanced with its proprietary anti-exhaustion technologies for patients with solid tumors or hematologic malignancies. The Company's investigational therapies use the patient's own cells as the starting point to generate highly tumor-reactive, longer-lasting functional T cells with enhanced ability to resist exhaustion and kill cancer cells. Its technologies are designed to generate T cells with the ability to persist and self-renew while driving tumor cytotoxicity. Its two product candidates, LYL797 and LYL845, are in Phase I clinical development, and an additional product candidate, LYL119, is entering Phase I clinical development. The Company is also engaged in accelerating the development of IMPT-314, a dual-targeting CD19/20 chimeric antigen receptor (CAR) T-cell product candidate for hematologic malignancies, including B-cell non-Hodgkin lymphoma.

Growing

The company is in a growing phase, with the latest annual income totaling USD 61.00K.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 61.00K.

Overvalued

The company’s latest PE is -0.74, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 9.60M shares, decreasing 6.64% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 442.63K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-06

The company's current financial score is 6.01, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 8.00K, representing a year-over-year decrease of 38.46%, while its net profit experienced a year-over-year decrease of 6.82%.

Score

Industry at a Glance

Previous score

6.01

Change



Financials

7.40

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.42

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.56

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Lyell Immunopharma Inc's Company Valuation

Currency: USD Updated: 2025-11-06

The company’s current valuation score is 8.60, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -0.74, which is -98.21% below the recent high of -0.01 and -625.66% above the recent low of -5.34.

Score

Industry at a Glance

Previous score

8.60

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 125/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-06

The company’s current earnings forecast score is 6.00, which is lower than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Lyell Immunopharma Inc is 12.00, with a high of 20.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

6.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Hold

Current Rating

14.000

Target Price

-21.70%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Lyell Immunopharma Inc

LYEL

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-06

The company’s current price momentum score is 9.05, which is higher than the Biotechnology & Medical Research industry's average of 6.45. Sideways: Currently, the stock price is trading between the resistance level at 19.65 and the support level at 15.89, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.08

Change

1.97

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

-0.350

Neutral

RSI(14)

59.447

Neutral

STOCH(KDJ)(9,3,3)

59.602

Buy

ATR(14)

1.214

Low Volatility

CCI(14)

32.485

Neutral

Williams %R

25.000

Buy

TRIX(12,20)

0.279

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

16.716

Buy

MA10

16.828

Buy

MA20

17.003

Buy

MA50

15.161

Buy

MA100

12.766

Buy

MA200

7.199

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-06

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 49.96%, representing a quarter-over-quarter decrease of 32.37%. The largest institutional shareholder is The Vanguard, holding a total of 442.63K shares, representing 2.30% of shares outstanding, with 31.07% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

ARCH Venture Partners

1.82M

-0.00%

GSK plc

1.51M

Foresite Capital Management, LLC

1.21M

-0.00%

Gates Frontier, L.L.C.

1.04M

Explore Investments LLC

1.04M

MWG Management, Ltd.

1.01M

-0.00%

Orland Properties Ltd

754.70K

Decheng Capital LLC

595.47K

-0.00%

Almitas Capital LLC

580.00K

+367.25%

VenBio Partners LLC

473.48K

+33.33%

Risk Assessment

Currency: USD Updated: 2025-11-06

The company’s current risk assessment score is 2.34, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is -0.08. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.